Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on redefining psychiatry by leveraging individualsâ neurobiology to develop personalized and effective treatment options. Through insights derived from the Companyâs scalable and proprietary Precision Psychiatry Platform, which applies rigorous data science and robust analytics to data gathered by neurocognitive assessments, electroencephalography, and wearable devices, the Company aims to discover brain-based biomarkers to better identify which patients are more likely to respond to its novel product candidates. Its pipeline consists of five clinical-stage assets, such as ALTO-100, ALTO-202, ALTO-300, ALTO-101, and ALTO-203, which target depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers. Its pipeline also includes novel drug candidates in depression, post-traumatic stress disorder (PTSD), and other mental health conditions.
ALTO NEUROSCIENCE, INC. 
